Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
Rapport Therapeutics, Inc. (RAPP) Stock Price & Analysis
13 Followers
RAPP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.00 - $28.08
Previous Close$23.05
Volume49.28K
Average Volume (3M)251.16K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$193.24M
Total Debt (Recent Filing)$686.00K
Price to Earnings (P/E)―
Beta5.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding35,376,457
10 Day Avg. Volume501,535
30 Day Avg. Volume251,156
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$35.00Price Target Upside51.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Rapport Therapeutics, Inc. News
Options Prices
Currently, No data available
---
Ownership Overview
40.30% Insiders
0.00% Mutual Funds
0.20% Other Institutional Investors
59.50% Public Companies and
Individual Investors
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $18.00 and its highest was $28.08 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 34,317,635 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
---
Rapport Therapeutics, Inc. Stock Smart Score
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
---
RAPP Stock 12 Month Forecast
Average Price Target
$35.00
▲(51.84% Upside)
Technical Analysis
Best Analysts Covering RAPP
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-7.80%
initiated a buy rating 26 days ago
Copying Paul Matteis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -7.80% per trade.
---